Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04338620

Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC

Non-small-cell Lung Cancer (NSCLC) Clinical Trial

Official title:
An Explorative Study on Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable Non-small-cell Lung Carcinoma

Clinical Trial Summary

Explorative study, which evaluates the effect of Camrelizumab combined with albumin-bound paclitaxel and platinum in neoadjuvant treatment of resectable non-small-cell lung carcinoma.

Clinical Trial Description

This is a multicenter, randomized, open parallel controlled trial to evaluate the efficacy and safety of camrelizumab combined with albumin-bound paclitaxel and platinum versus albumin-bound paclitaxel combined with platinum in resectable stage IIIA -IIIB NSCLC (IIIB is limited toT3N2). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04338620
Study type Interventional
Source Tang-Du Hospital
Contact
Status Active, not recruiting
Phase Phase 2
Start date April 7, 2020
Completion date November 1, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT03725475 - A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer Patients
Completed NCT01874678 - A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer N/A
Recruiting NCT06357598 - Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer Phase 4
Recruiting NCT02448992 - Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer Phase 2/Phase 3
Completed NCT02113813 - A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations Phase 1
Completed NCT06232967 - PPIO-006 Primary Tumor Resection for IVa NSCLC